Post on 07-Jul-2015
transcript
ANTIBIOTIC THERAPY IN THE INTENSIVE CARE
UNITDr amrita
Moderator : dr amit rastogi
THE ACTION OF ANTIMICROBIAL DRUGS
Figure 20.2
PROTEIN SYNTHESIS INHIBITORS
Figure 20.4
BETA LACTAMS
• Narrow spectrum
• Narrow spectrum pEnicillinase susceptible. Penicillin
• Very-narrow-spectrum penicillinase-resistant drugs
• Methicillin
• Nafacillin
• Oxacillin
• Wide spectrum
• Wider-spectrum penicillinase-susceptible drugs
• Ampicillin and amoxicillin.
• Piperacillin and ticarcillin.
• Wide spectrum pEnicillinase resistant drugs
• Carbapenem
• Imipinem
• Meropenem
• Doripinem
• Ertapenem
THE CEPHALOSPORIN FAMILY
OTHER CELL WALL INHIBITORS
• Monobactams
• Aztreonams
• Vancomycin
• Telavancin
• Dalacin
• teichoplanin
AMINOGLYCOSIDES
• Gentamycin
• Tobramcin
• Amikacin
• Toxicity profile
• Ototoxicity
• Nephrotoxicity
• Blocking neuromuscular transmission
• hypersensitivity
PROTEIN SYNTHESIS INHIBITORS
• Linezolid
• Quinupristin/Dalfopristin
• Daptomycin
• Tigecycline
ANTIMICROBIALS WITH ACTIVITY AGAINST ANAEROBES
• Metronidazole
• clindamycin
PHARMACOKINETICS AND PHARMACODYNAMICS OF ANTIBIOTICS
SPECIAL CONSIDERATIONS IN THE CRITICALLY ILL PATIENT
• Volume of distribution
• Metabolism
• Clearance : ranal hyper and hypo filtration
• hypoalbunaemia
HOW TO START
• Loading dose = target plasma conc * volume of distribution
• High loading doses for hydrophilic drugs like beta lactams , vancomycin , and
aminoglycosides
• Lipophilic drugs like macrolides,linezolid,tetracyclins do not require a high loading
dose
• Renal and hepatic function do not affect loading dose
PHARMACOKINETIC AND PHARMACODYNAMICS PROPERTIES OF ANTIBIOTICS
• Minimum inhibitory concentration : The MIC is the lowest concentration of an
antibiotic that completely inhibits the growth of a microorganism in vitro. While the
MIC is a good indicator of the potency of an antibiotic, it indicates nothing about the
time course of antimicrobial activity
• Parameters quantifying serum level :
• Peak serum level : Cmax
• Trough level : Cmin
• Area Under the serum concentration time Curve (AUC) : indicates the amount of drug
PARAMETERS INDICATING ANTIBIOTIC ACTIVITY
• he Peak/MIC ratio, Cpmax divided by the MIC.
• the T>MIC, percentage of a dosage interval in which the serum level exceeds the
MIC.
• and the 24h-AUC/MIC ratio. determined by dividing the 24-hour-AUC by the MIC
Pattern of Activity Antibiotics Goal of Therapy PK/PD Parameter
Type I
Concentration-dependent killing and
Prolonged persistent effects
Aminoglycosides
Daptomycin
Fluoroquinolones
Ketolides
Maximize concentrations24h-AUC/MIC
Peak/MIC
Type II
Time-dependent killing and
Minimal persistent effects
Carbapenems
Cephalosporins
Erythromycin
Linezolid
Penicillins
Maximize duration of exposure T>MIC
Type III
Time-dependent killing and
Moderate to prolonged persistent effects.
Azithromycin
Clindamycin
Oxazolidinones
Tetracyclines
Vancomycin
Maximize amount of drug 24h-AUC/MIC
DOSING OF A CONCENTRATION DEPENDANT ANTIBIOTIC
DOSING OF A TIME DEPENDANT ANTIBIOTIC
• Multiple small dosing to obtain the
maximum t > MIC
• Role of prolonged infusions
ANTIBIOTIC RESISTANCE
• Common mechanisms
• Impermeability of the drug:
• alteration in target molecules
• enzymatic drug modifications
• Efflux
• both chromosomal mutations or genetic transfer ( plasmids ) can be responsible for
the resistance acquisition,
FACTORS RESPONSIBLE FOR ANTIBIOTIC RESISTANCE
• Lack of education
• Hospital acquired infections
• Use of antibiotics in agriculture or aquaculture
• Environmental factors
• Use in household products
SOME COMMON RESISTANT STRAINS : GRAM POSITIVE
• Methicillin resistant Staplylococcus aureus (MRSA)
• Vancomycin intermediate staph. Aureus ( VISA )
• Enterococcus- HLAR
• Multi drug resistant strep pneumoniae
SOME COMMON RESISTANT STRAINS : GRAM NEGATIVE
• Extended-Spectrum b-Lactamase –Producing Enterobacteriaceae
• Antibiotic options carbapenems,
• tigecycline
• Carbapenemase producing enterobacteriaciae
• The delhi metalloprotease
• No susceptibility to any beta lactam or other higher antibiotics
• Susceptible to tigecycline and colistin
• Multi drug resistant pseudomonas MDR P aeruginosa are strains that are
resistant to 2 or more classes of antibiotics
• Antipseudomonal Penicillins with or with out beta lactamases
• Piperacillin tazobactum
• Ticarcillin
• Aztreonam
• Caeftazidime in combination with aminoglycosides
• Carbapenems : imipinem > doripinem > meropenem.etrapenem has no role against
pseudomonas.
• colistin
ANTIBIOTIC THERAPY IN THE ICU
ANTIBIOTIC STEWARDSHIP
• The Centers for Disease Control and Prevention (CDC) estimates more than two
million people are infected with antibiotic-resistant organisms, resulting in
approximately 23,000 deaths annually.
• Has recommended the setting up of special bodies in all acute care hospitals for the
optimization of antibiotic use-called antibiotic stewardship programmes.
SPECIFIC INTERVENTIONS TO IMPROVE ANTIBIOTIC USE
• formal procedure for all clinicians to review the appropriateness of all antibiotics 48
hours after the initial orders (e.g. antibiotic time out)
• specified antibiotic agents need to be approved by a physician or pharmacist prior to
dispensing
• physician or pharmacist to review courses of therapy for specified antibiotic agents
(i.e., prospective audit with feedback)
• Automatic changes from intravenous to oral antibiotic therapy in appropriate
situations
• Dose adjustments in cases of organ dysfunction
• Dose optimization (pharmacokinetics/pharmacodynamics) to optimize the treatment
of organisms with reduced susceptibility
• Automatic alerts in situations where therapy might be unnecessarily duplicative
• Time-sensitive automatic stop orders for specified antibiotic prescriptions
• track rates of C. difficile infection
• Monitor total amounts of antibiotics used
ANTIBIOTIC STRATEGIES TO COMBAT RESISTANCE
Blast them
Fool them
Stop irritating them.
ANTIBIOTIC STRATEGY FOR SKIN AND SOFT TISSUE INFECTION
ANTIBIOTIC STRATEGY FOR COMMUNITY ACQUIRED PNEUMONIA
• A b-lactam (cefotaxime, ceftriaxone, or ampicillin-sulbactam)
azithromycin (level II evidence) or a respiratory fluoroquinolone
• If Pseudomonas is a consideration
• An antipneumococcal, antipseudomonal b-lactam (piperacillintazobactam,
cefepime, imipenem, or meropenem) plus
• either ciprofloxacin or levofloxacin (750 mg)
+
• Or
• The above b-lactam plus an aminoglycoside and azithromycin
• or
• The above b-lactam plus an aminoglycoside and an antipneumococcal
fluoroquinolone (for penicillin-allergic patients,
substitute aztreonam for above b-lactam)
ANTIBIOTIC INFECTION FOR INTRA ABDOMINAL INFECTIONS